Parkin interacting polypeptides and methods of use

Details Parkin interacting polypeptides and methods of use Parkin interacting polypeptides and methods of use

2011-04-19

2011-04-19

Stucker, Jeffrey (Department: 1649)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S007100

Reexamination Certificate

active

07927786

ABSTRACT:
The invention provides parkin binding polypeptides and encoding nucleic acids. The invention also provides antibodies specific for the parkin binding polypeptides. The invention additionally provides methods of detecting a parkin binding polypeptide and detecting a nucleic acid encoding a parkin binding polypeptide. The invention further provides methods of using a parkin binding polypeptide. In one embodiment, the invention provides a method of identifying a candidate drug for treating Parkinson's disease by contacting a parkin binding polypeptide with one or more compounds and identifying a compound that alters the activity of the parkin binding polypeptide.

REFERENCES:
patent: 2002/0155577 (2002-10-01), Koutnikova
patent: WO 02/24721 (2002-03-01), None
Abbas et al.,“A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease,”Hum. Mol. Genet. 8:567-574 (1999).
Beites et al., “The septin CDCrel-1 binds syntaxin and inhibits exocytosis,”Nat. Neurosci. 2(5):434-439 (1999).
Berton et al., “Synaptotagmin I and IV define distinct populations of neuronal transport vesicles,”Eur. J. Neurosci. 12:1294-1302 (2000).
Bommert et al., “Inhibition of neurotransmitter release by C2-domain peptides implicates synaptotagmin in exocytosis,”Nature363:163-165 (1993).
Bonifati et al., “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism,”Science299:256-259 (2003).
Chung et al., “Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease,”Nat. Med. 7:1144-1150 (2001).
Corti et al., “The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration,”Hum Mol. Genet. 12:1427-1437 (2003).
Damier et al., “The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease,”Brain122:1437-1448 (1999).
Davis et al., “Kinetics of synaptotagmin responses to Ca2+ and assembly with the core Snare complex onto membranes,”Neuron. 24:363-376 (1999).
Diantonio et al., “The effect on synaptic physiology of synaptotagmin mutations in Drosophila,”Neuron. 12:909-920 (1993).
Diantonio et al., “Synaptic transmission persists in synaptotagmin mutants of Drosophila,”Cell73:1281-1290 (1993).
Elferink et al., “A role for synaptotagmin (p65) in regulated exocytosis,”Cell72:153-159 (1993).
Engelender et al., “Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions,”Nat. Genet. 22:110-114 (1999).
Fernandez-Chacon et al., “Synaptotagmin I functions as a calcium regulator of release probability,”Nature410:41-49 (2001).
Finney et al., “The cellular protein level of parkin is regulated by its ubiquitin-like domain,”J. Biol. Chem. 278:16054-16058 (2003).
Fukuda and Mikoshiba, “Characterization of KIAA1427 protein as an atypical synaptotagmin (Syt XIII),”Biochem. J. 354:249-257 (2001).
Fukuda et al., “A unique spacer domain of synaptotagmin IV is essential for Golgi localization,”J. Neurochem. 77:730-740 (2001).
Fukuda et al., “Nerve growth factor-dependent sorting of synaptotagmin IV protein to mature dense-core vesicles that undergo calcium-dependent exocytosis in PC12 cells,”J. Biol. Chem. 278:3220-3226 (2003).
Geppert et al., “Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse,”Cell79(4):717-727 (1994).
Gerona et al., “The C terminus of SNAP25 is essential for Ca2+-dependent binding of synaptotagmin to SNARE complexes,”J. Biol. Chem. 275:6328-6336 (2000).
Hayashi et al., “An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene,”Mov. Disord. 15:884-888 (2000).
Huynh et al., “Parkin is associated with actin filaments in neuronal and nonneuronal cells,”Ann. Neurol. 48:737-744 (2000).
Huynh et al., “Parkin colocalizes with actin filaments and synaptic vesicles, and interacts with synaptotagmin XI,”Abstr. Soc. Neurosci. 27:607, abstract 233.1, (2001).
Huynh et al., “Interaction of Parkin with vesicle-associated proteins,”Neurology58 (suppl. 3); A410 abstract S53.007 (2002).
Huynh et al., “The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI,”Hum. Mol. Genet.12(20):2587-2597 (2003).
Ibata et al., “Synaptotagmin IV is present at the golgi and distal parts of neuritis,”J. Neurochem. 74:518-526 (2000).
Imai et al., “An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin,”Cell105:891-902 (2001).
Imai et al., “CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity,”Mol. Cell. 10:55-67 (2002).
Imai et al., “Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity,”J. Biol. Chem. 275:35661-35664 (2000).
Ishikawa and Takahashi, “Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism,”J. Neurol. 245(Suppl 3): p. 4-p. 9 (1998).
Ishikawa and Tsuji, “Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism,”Neurology47:160-166 (1996).
Joazeiro and Weissman, “RING finger proteins: mediators of ubiquitin ligase activity,”Cell102:549-552 (2000).
Jorgensen et al., “Defective recycling of synaptic vesicles in synaptotagmin mutants of Caenorhabditis elegans,”Nature378:196-199 (1995).
Kitada et al., “Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism,”Nature392:605-608 (1998).
Le et al., “Mutations in NR4A2 associated with familial Parkinson 33:85-89 (2003). disease,” Nat. Genet. 33:85-89 (2003).
Leveque et al., “Calcium-dependent dissociation of synaptotagmin from synaptic SNARE complexes,”J. Neurochem. 74:367-374 (2000).
Li et al., “Ca2+-dependent and -independent activities of neural and non-neural synaptotagmins,”Nature375:594-599 (1995).
Matsumine, “A loss-of-function mechanism of nigral neuron death without Lewy body formation: autosomal recessive juvenile parkinsonism (AR-JP),”J. Neurol. 245(Suppl. 3):10-14 (1998).
Mori et al., “Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q,”Neurology51:890-892 (1998).
Murphey and Godenschwege, “New roles for ubiquitin in the assembly and function of neuronal circuits,”Neuron36:5-8 (2002).
Naoi et al., “Cell death of dopamine neurons in aging and Parkinson's disease,”Mech. Ageing Dev. 111:175-188 (1999).
Polymeropoulos et al., “Mutation in the alpha-synuclein gene identified in families with Parkinson's disease,”Science276:2045-2047 (1997).
Reist et al., “Morphologically docked synaptic vesicles are reduced in synaptotagmin mutants of Drosophila,”J. Neurosci. 18:7662-7673 (1998).
Ren et al., “Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation,”J. Neurosci. 23:3316-3324 (2003).
Ribeiro et al., “Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein,”J. Biol. Chem. 277:23927-23933 (2002).
Schiavo et al., “Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synap

Affiliated with

Also associated with

Rating

Parkin interacting polypeptides and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Parkin interacting polypeptides and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parkin interacting polypeptides and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2719449